| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | — |
| R&D Expense | $142.0M | -17.1% |
| SG&A Expense | $86.5M | -15.2% |
| Operating Income | -$231.7M | +15.2% |
| Interest Expense | $1.9M | +0.3% |
| Pre-tax Income | -$223.1M | +13.8% |
| Income Tax | $0 | — |
| Net Income | -$223.1M | +13.8% |
| EPS (Basic) | -$2.01 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $77.6M | -52.6% |
| Short-term Investments | $111.4M | -46.6% |
| Current Assets | $192.7M | -49.0% |
| Total Assets | $330.4M | -37.4% |
| Current Liabilities | $30.2M | -25.8% |
| Total Liabilities | $53.2M | -17.4% |
| Stockholders' Equity | $277.2M | -40.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$190.0M | +9.4% |
| Capital Expenditures | $440K | -92.5% |
| Investing Cash Flow | $103.8M | -21.2% |
| Financing Cash Flow | $148K | -99.9% |
| Free Cash Flow | -$190.5M | +11.7% |
| +26.4% |
| EPS (Diluted) | -$2.01 | +26.4% |